Abstract
Cancer, a complex disease, requires innovative treatment strategies, such as multi-target therapy, which seeks to maximize therapeutic efficacy by simultaneously attacking multiple biological targets. In this context, the focus on hybrid inhibitors, capable of acting on several targets and enhancing synergistic effects, has been gaining prominence, especially in the inhibition of HDACs an…